Key Takeaways
- Domestic formulations resilient, exports mixed: Domestic business grew 10% (13% ex-antimalarials), making Ipca the second fastest-growing top-20 IPM player, while API declined ~15% and export generics grew just 4%.
- Margin compression from deliberate investment: EBITDA margin fell to 21.04% from 23.05% YoY, driven by a ~₹16 crore energy cost increase and the upfront cost of 1,200 new MRs who will take ~2 years to break even.
- API and generics guidance cut sharply: API is now expected to decline ~2% for the full year, and export generics guidance was revised from ~5% growth to a 2-3% decline, driven by demand slowdown in Latin America and Asia.
- Gross margin tailwind building with a lag: Raw material costs are softening across intermediates, solvents, and packaging, but the benefit is delayed by FIFO inventory accounting; management expects a greater impact in coming quarters.
- What to watch next quarter: Whether the guided H2 recovery in API and UK actually materializes, the pace of gross margin improvement as lower-cost inventory flows through, and any update on US FDA re-inspection timing.
Domestic Formulations: The Growth Engine
- Broad-based therapy outperformance: Pain grew 21% vs 12% IPM, CNS 30% vs 9%, Dermatology 14% vs 3%, Urology 35% vs 17%, and Cough & Cold 24% vs 12%. Anti-infectives grew 5% vs 4%.
- Cardiovascular the lone laggard: Cardiac grew ~4% vs ~6% IPM because the business was reorganized and restructured this year, with teams still stabilizing. Management expects streamlining in one more quarter.
- Market share steadily climbing: Ipca's IPM share improved to ~1.91% in Q2 FY23, up from 1.86% over the prior four years and 1.59% in 2018.
- MR investment is a deliberate margin drag: Over 1,200 MRs were added in the last 2-3 quarters (1,500 targeted for the full year), and new recruits take ~2 years to become productive and break even. They are currently a cost with little productivity, and the full-year marketing cost will remain elevated before normalizing to 8-10% growth from next year.
Management: "Whenever you recruit the new people, it take time to-- for them to become productive. It will take almost around 2 years' time for them to start giving breakeven to the company. ... 3rd year onwards they will start contributing profits to the company."
API & Export Generics: The Problem Children
- API declined ~15% in Q2: The ~₹50 crore impact came mainly from Latin America and Asia, where demand slowed and customers postponed order executions. Saturn category pricing pressure contributed but the decline there was small. European and India API business did well.
- Full-year API guidance cut to negative: Management expects a ~2% decline for FY23, with some recovery in H2 but overall degrowth of 2-3%. The market itself is not growing at prior levels.
- Export generics guidance also revised down: From ~5% growth to a 2-3% decline by year-end, reflecting the broader demand and regulatory headwinds.
- Branded export lumpiness explained: During the Ukraine war onset, shipments were cut sharply as the Ruble-Dollar rate more than doubled; channel inventories were drawn down. When the currency stabilized around 60-70, replenishment drove ~93% growth in that market in Q2. Full-year CIS growth projection remains ~15%.
Management: "The major geographies where the impact has come is, one is Latin America, and one is Asia. These are the two geographies where the major impact we have seen is, basically because of slowdown in the demand and customers postponing the order executions."
Margins: Compressed Today, Building Blocks Tomorrow
- EBITDA margin fell ~200 bps YoY to 21.04%: The decline was driven by energy costs (up ~₹16 crore from coal, SSD, and electricity rate revisions) and significantly higher marketing costs from the MR build-out, post-COVID travel normalization, higher per-km travel rates, and increased promotional spend.
- Gross margin improvement is in the pipeline: Prices of intermediates, starting materials, solvents, API, aluminum foil, plastic, PVC, and PVDC are all softening. Material costs improved 0.26% YoY (32.83% vs 33.09%), but the full benefit is delayed by FIFO inventory accounting: higher-cost Q1 inventory is still being consumed in Q2. Greater impact expected in coming quarters.
- Consolidated margin differential explained: The ~200 bps gap between standalone and consolidated EBITDA margin this quarter was mainly due to exceptional losses in Bayshore accounts from COVID sale returns and post-COVID discounts. Ramdev and Pisgah also contributed; Ramdev may take 2-3 quarters to recover, Pisgah another year or so.
- Full-year margin guided at ~21%: Material cost trends are improving, but energy and marketing costs are the offsets. Newly added people will add a little to margin quarter by quarter as they become productive.
Management: "Actually speaking, this financial year is very difficult, cost pressure, demand issues, so many regulatory problems with the API, Nitrosamines impurity and, plus, over and above that we have added about 1500 people in the domestic market. In spite of that we are delivering this kind of EBITDA margin."
UK & Institutional: Transition Stories
- UK business hit by Bristol contract loss in H1: Q1 and Q2 were impacted by the loss of a significant Bristol business. From Q3 onwards, the business is only ~₹9-10 crore of distributor-related revenue. Good market share has been gained on launched products, and 7-8 products are under launch with 20+ including SPUs planned for H2. A marginal full-year decline is expected but good traction is visible.
- Institutional/antimalarial not a growth story: Retendering caused a slowdown in ordering, and antimalarial as a category is not doing well due to climatic conditions. India antimalarial business declined significantly. Management is not projecting significant growth over the longer term.
Management: "We are not projecting a significant growth as far as this category of business is concerned. And on institutional business we are there are only antimalarials. So, that's the kind of scenario over a longer period of time."
Facilities & Regulatory: Waiting on Catalysts
- Dewas unit 1 commercialized, costs arriving: Validation programs for ~10 APIs have started, and some intermediate business for captive consumption began earlier. Cost addition in H2 will be ~₹2.5 crore per month plus additional depreciation. No meaningful top-line contribution is expected for 1 year, until all products are filed and regulatory inspections happen. First filing is at least ~6 months away, with inspections 3-5 months after filing.
- Silvassa recently inspected by UK MHRA: Accreditation is expected in about a month.
- US FDA re-inspection: status quo: No timeline provided; the company is awaiting re-inspection.
- Continuous manufacturing progressing slowly: A second plant is likely to be built at Aurangabad. Some steps have had significant success, but chemistries using corrosive chemicals like Phosphoric acid and Phosphorus Oxychloride are still being consulted. Currently a mix of continuous and conventional steps is in use.
Management: "So, we see that overall, for 1 year nothing meaningful contributions would come from this site, till the time we file all the products and till the time regulatory inspections of the site happens."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| API full-year growth | Decline of ~2% (2-3% degrowth) | FY23 |
| Export generics full-year growth | 2-3% degrowth (revised from ~5% growth) | FY23 |
| EBITDA margin | Remain around 21% | FY23 |
| Marketing cost normalization | Normal cost increase of 8-10% | From FY24 |
| CIS/Russia branded export growth | ~15% growth | FY23 |
| UK full-year performance | Marginal decline | FY23 |
| Dewas meaningful contribution | No meaningful contribution for 1 year | ~Q3 FY24 |
| New MR breakeven | ~2 years to breakeven; profit contribution from year 3 | FY25 onwards |
| Ramdev recovery | Back on track | 2-3 quarters |
| Pisgah recovery | Recovery | Another year or so |
| Silvassa UK MHRA accreditation | Expected | ~1 month |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue (domestic formulation) | 10% growth, antimalarial business declined ~19% |
| Revenue (domestic formulation ex-antimalarials) | ~13% growth |
| Revenue (export promotional business) | ~33% growth |
| Revenue (export generic business, including institutional) | ~8% growth |
| Revenue (institutional business) | ~12% growth |
| Revenue (generics business) | ~4% growth |
| Revenue (API business) | ~15% decline, full FY23 expected decline of 2-3% |
| Material cost to income | 32.83%, improved 0.26 ppt YoY from 33.09% |
| Other expenditure | ~23% increase YoY, energy cost higher by ~₹16 cr |
| EBITDA margin (standalone) | 21.04%, vs 23.05% in Q2 FY22 |
| EBITDA margin guidance (full year) | ~21% |
| India business gross margin | 67-68%, consistent, not materially changed |
| MR addition cost impact (full FY23) | ₹120 cr to ₹150 cr overall, ~₹100 cr from new people added during the year |
| Market share (IPM) | ~1.91%, up from 1.86% over last 4 years |
| IPM rank | 17th, gained 3 ranks over 2018 |
| Pain segment growth (domestic) | ~21% vs market growth of ~12% |
| Cardiac segment growth (domestic) | ~4% vs market growth of ~7% |
| CNS segment growth (domestic) | ~30% vs market growth of ~9% |
| Urology segment growth (domestic) | ~35% vs market growth of ~17% |
| Dermatology segment growth (domestic) | ~14% vs market growth of ~3% |
| Anti-infectives segment growth (domestic) | ~5% vs market growth of ~4% |
| Cough and cold segment growth (domestic) | ~24% vs market growth of ~12% |
| Branded export (CIS/Russia) growth | ~93% in Q2, full-year projection ~15% |
| USD realization (Q2) | ₹79.85/Dollar, average for H1 less than ₹80/Dollar |
| Silvassa facility utilization | 15-20% capacity |
| SEZ Indore facility utilization | ~35-40% capacity |
| Tax rate (effective, including deferred tax) | ~28-29% |
| Dewas facility cost addition (H2 FY23) | ~₹2.5 cr per month plus additional depreciation |
| Generic business guidance (full FY23, revised) | 2-3% degrowth, vs earlier ~5% growth guidance |
| EBITDA margin target (3-4 years out) | 24-25% |